Letrozol Tarbis Farma

Letrozole, the active ingredient in Letrozol Tarbis Farma, is an aromatase inhibitor presented as a tablet for oral use. It is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy and for advanced disease.

GNH USA supplies Letrozol Tarbis Farma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the EU‑origin product to oncology centres, hospitals and pharmacies worldwide while ensuring quality and regulatory compliance.

Letrozole is used in the management of estrogen‑dependent breast cancer, acting on the aromatase pathway.

Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen production to slow tumor growth. Adjuvant treatment of early breast cancer: lowers risk of recurrence after surgery. Metastatic breast cancer in postmenopausal patients: provides disease control when cancer has spread.

Letrozole may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature and sweating. - Joint and muscle pain: arthralgia and myalgia affecting mobility. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Bone density loss: decreased mineral content leading to osteoporosis risk.

Serious or Rare Side Effects: - Severe cardiovascular events: including myocardial infarction or stroke. - Liver toxicity: elevated transaminases or hepatitis. - Severe allergic reactions: anaphylaxis or angioedema.

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure patient safety.

Assess bone health: baseline DEXA scan recommended due to risk of osteoporosis. Monitor liver function: periodic tests to detect hepatotoxicity. Evaluate cardiovascular risk: consider history of thromboembolic disease. Avoid use in pregnancy: drug is contraindicated in pregnant women. Drug interactions: review concomitant medications that affect estrogen levels. Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use of estrogen replacement therapy: negates aromatase inhibition. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels. - Tamoxifen: antagonistic effects on estrogen pathways.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect, monitor INR. - SSRIs/SNRIs (e.g., fluoxetine): may affect metabolism, observe for side effects. - Cholesterol‑lowering agents (e.g., statins): monitor liver enzymes.